Understanding HMP Global Market Access Insights' New Payer Report Series

Article

Understanding HMP Global Market Access Insights' New Payer Report Series

March 10, 2022
Authors
Topics

Welcome to the March edition of our Monthly Insight Series. This month we review several highlights from our December 2021 Special Topic Report on Payers.

Reading a tablet

Greetings From San Mateo!

Welcome to the March edition of our Monthly Insight Series. This month we review several highlights from our December 2021 Special Topic Report on Payers.

Why Payers? The insurance marketplace has become increasingly consolidated, and companies are looking for new avenues for growth. Large, horizontal mergers reached a standstill when the Cigna + Anthem merger was blocked by a U.S. district court resulting in a termination of the agreement. Payers are now focusing on vertical integration, and blurring the lines between insurer, PBM, SP, and Provider.

Payers are, in some cases, now acting as "virtual IDNs" enabling them to manage the initial referral and capture downstream revenues (see below).

 

Grappling With the (Payer) Octopus 

We see several trends continuing to accelerate in this "Vertical Era": 

1. Payers and Providers will increasingly compete to control patients. Expect provider consolidation as competition weeds out the weak. Monitor payer expansion from "easy" opportunities such as senior care into high-cost and high-complexity areas including oncology. 

2. "Virtual First" plans become commonplace. Payers save money by asking patients to initiate care using a phone or video encounter. Patients are then directed to the insurers' preferred providers for subsequent care, subject to strict prescribing controls. These narrow specialty networks increase plans' influence on treatment selection.

3. Manufacturers will need to track their relationships and financial arrangements across an entire vertical payer organization. Vertical payers will inevitably have internal conflicts as priorities among subsidiaries vary, most likely between an insurer’s search for low total cost of care and a PBM’s search for rebates, admin, and data fees. Manufacturers should assess each vertical payer’s level of integration and adapt their commercial interactions to optimize their results across the entire payer vertical.

If you like what you see, stay tuned! We are planning to release a payer podcast this April. As always, please reach out with any questions or comments you may have.

All the best...
-- HMP Market Access Insights Team

The Latest

Revolutionizing Cancer Care: EOM's Second Wind and its Current Impact on Community Oncology Practices

The second Enhancing Oncology Model (EOM) application cycle closed on September 16, signaling shifts in community oncology. Explore our 2024 Community Oncology Report to understand EOM’s current impact and changes from this round.

Ashutosh Sheth
Key takeaways from CPC+CBEx 2024
Article
Bispecific Therapies in Community Oncology: Bridging Insights from CPC+CBEx and Beyond

Explore key takeaways from CPC+CBEx on bispecific therapies, highlighting collaboration between hospitals and community practices to expand access and tackle financial challenges.

Daniel Buchenberger
Figure 1: Community Oncology Actions to Address Any Potential Impact of the IRA   Source: HMP Market Access Insights 2024 Community, and Payer Oncology Trend Report.
Article
Community Oncology: Awareness v Action in the Face of the IRA

The Inflation Reduction Act (IRA) will significantly impact community oncology practice financials. As we approach this shift, our latest research from the 2024 Community Oncology Report reveals a current gap between awareness and action.

Emma Bijesse